Actualités

Five thousand dollars a month in spendable dividend income works out to $60,000 per year after federal tax, roughly equivalent to the salary of a typical police officer in Indiana. The headline yield shown on a brokerage statement does not tell the full story. Taxes, the type of distributions received, and future dividend growth all ... Get Paid Like an Indiana Police Officer With $5,000 a Month in Dividend Income After Taxes

The Firelink platform delivers protein-degrading drugs directly into KRAS-driven tumor cells

More than a simple climb, the drugmaker's stock re-rated on a growth story that somehow keeps getting bigger.

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and

A retiree’s $40,000 dividend income stream sounds modest next to a neighbor’s $90,000. But the growth rate often matters more than the starting number. A portfolio generating $40,000 today that grows its income by 8% annually produces roughly $86,000 in ten years and more than $186,000 in twenty. That is the power of compounding. The ... The Dividend Growth Portfolio That Starts at $40,000 a Year and Ends at $150,000

ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.

Generating $7,500 per month in dividend income requires producing $90,000 annually from an investment portfolio. That income level is roughly equivalent to the salary of a registered nurse, based on recent U.S. Bureau of Labor Statistics wage data. As a result, it serves as a useful benchmark for households pursuing financial independence or planning for ... How to Replace a Registered Nurse’s Salary with $7,500 a Month in Dividend Income

Johnson & Johnson (JNJ) said Monday that it has agreed to acquire cancer drug developer Firefly Bio

The deal targets KRAS-driven tumors, which J&J says have limited treatment options and survival measured in months

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.

Johnson & Johnson has agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that bolsters the drugmaker’s oncology pipeline.

The drugmaker's recent outperformance is a sideshow to its more valuable, long-term trait for investors.

June 8 (Reuters) - Johnson & Johnson said on Monday it will acquire biotech Firefly Bio for $1 billion in cash, as it looks to expand its cancer drug pipeline.

Johnson & Johnson (NYSE:JNJ) is one of the cheap robotics stocks to buy right now. On May 12, Johnson & Johnson (NYSE:JNJ) confirmed the global launch of the Shockwave C2 Aero Coronary IVL Catheter for the treatment of calcified coronary artery disease, as it seeks to redefine the standards of coronary IVL with efficient, predictable […]

The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.

The goal of our Best Companies for the Future list is to find companies that meet this unprecedented historical moment

Johnson & Johnson takes a licking, and the dividend keeps on ticking higher.

The Investing for Beginners Podcast recently revisited one of the most influential ideas in modern finance. That was Benjamin Graham’s concept of buying with a margin of safety. In fact, according to host Andrew Sather, Graham’s Columbia students went on to compound capital at extraordinary rates using the same principles applied to wildly different portfolios. ... These Investors Earned 20% to 33% Returns Using The Same Philosophy on Completely Different Stocks

Wondering whether Kenvue at around US$17.71 offers good value or just looks cheap on the surface? This article breaks down what that price really implies for you as a shareholder. The stock has inched up 2.5% over the last week and 0.2% over the last month, yet is still down 14.7% over the past year and up 2.3% year to date. This naturally raises questions about risk, sentiment, and entry points. Recent coverage has focused on Kenvue as a stand alone consumer health company following its...

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.

US stocks (^DJI, ^IXIC, ^GSPC) sink in Friday trading, the Nasdaq Composite leading losses and closing over 1,100 points lower (4.18%). The market is reacting to May's overwhelmingly positive labor data — 172,000 jobs added the US economy vs. estimates of 88,000 — raising investor concerns that the Federal Reserve may be inclined to hike interest rates. Yahoo Finance Markets and Data Editor Jared Blikre breaks down the day's biggest market moves.

In May 2026, Laser Photonics Corporation disclosed that Nasdaq had notified the company it was out of compliance due to a delayed Form 10-Q filing for the quarter ended March 31, 2026, starting a process that could eventually lead to delisting if the issue is not resolved within Nasdaq’s prescribed timelines. This filing setback comes as Laser Photonics is gaining higher visibility from U.S. defense evaluations of its Laser Shield Anti-Drone system, a major Navy follow-on contract for laser...

CereVasc is developing a minimally invasive treatment for the buildup of fluid in the brain.

Kimberly-Clark Corporation (NASDAQ:KMB) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer called it an “odd one,” as he commented: We need some staples. I’ve got an odd one. How about a stock I haven’t talked about at all? How about Kimberly-Clark? Here’s a premier Kleenex […]

Johnson & Johnson (NYSE:JNJ) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer highlighted the company’s billion-dollar drugs and growing businesses, as he stated: So I’m going to do something completely out of favor and recommend one that we’re buying for the Charitable Trust gingerly, as […]

Replacing $36,000 a year in income is roughly equivalent to generating the cash flow from a maximum Social Security benefit for a single retiree, or about $3,000 a month before taxes. A 66-year-old with $850,000 in a taxable brokerage account can build that income stream using five Dividend Aristocrats, relying on companies with decades-long records ... Five Boring Dividend Aristocrats That Quietly Pay $36,000 a Year on $850,000 Without a Single Yield Trap

J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.

Five Dividend Aristocrats with streaks ranging from 54 to 70 consecutive years of payout hikes are currently trading below Wall Street’s consensus price targets, and four of the five just beat their most recent EPS estimates. When a 64-year dividend raiser like Johnson & Johnson is raising 2026 EPS guidance to $11.45-$11.65 while still trading ... Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target

Here are three top-rated consumer dividend stocks that have yields above 3% and have made their way onto the coveted Zacks Rank #1 (Strong Buy) list.

In the latest trading session, Johnson & Johnson (JNJ) closed at $228.17, marking a +2.21% move from the previous day.